Related Experiment Video
Updated: Feb 8, 2026

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
Published on: October 14, 2016
Plasminogen activator inhibitor-1 activity and long-term outcome in patients with ST-elevation myocardial infarction
Marin Pavlov1, Vjeran Nikolić-Heitzler, Zdravko Babić
1Marin Pavlov, Department of Cardiology, Sestre Milosrdnice University Hospital Center, Vinogradska cesta 29, 10000 Zagreb, Croatia, marin.pavlov@gmail.com.
Insights
A significant rise in plasminogen activator inhibitor-1 (PAI-1) activity during ST-elevation myocardial infarction (STEMI) treatment predicts a higher risk of death within five years. This finding aids in stratifying mortality risk for STEMI patients undergoing primary PCI.
Area of Science:
- Cardiology
- Biomarkers
- Clinical Research
Background:
- ST-elevation myocardial infarction (STEMI) is a critical cardiovascular event.
- Early identification of patients at high risk for long-term mortality is crucial for effective treatment strategies.
- Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of fibrinolysis and has been implicated in cardiovascular disease.
Purpose of the Study:
- To investigate the association between the change in plasminogen activator inhibitor-1 (PAI-1) activity within 24 hours of STEMI treatment and 5-year mortality.
- To evaluate PAI-1 activity rise as a potential prognostic biomarker in STEMI patients treated with primary percutaneous coronary intervention (PCI).
Main Methods:
- A prospective cohort study enrolled 87 STEMI patients treated with primary PCI.
- PAI-1 activity was measured on admission and 24 hours post-treatment.
- Statistical analyses included ROC curves for predictive value, Cox regression for independent predictors, and linear regression for related covariates.
Main Results:
- PAI-1 activity rise demonstrated strong predictive value for 5-year mortality (AUC=0.748, optimal cut-off 3.7 U/mL).
- Patients with PAI-1 activity rise >3.7 U/mL exhibited significantly higher mortality (P<0.001).
- Independent predictors of death included PAI-1 rise and final Thrombolysis in Myocardial Infarction (TIMI) flow; PAI-1 rise correlated with heart failure, thrombus aspiration, and body weight.
Conclusions:
- An elevated PAI-1 activity rise (>3.7 U/mL) within 24 hours of primary PCI for STEMI is significantly associated with increased 5-year mortality.
- PAI-1 activity rise serves as a valuable prognostic marker in STEMI patients.
- Further research may explore therapeutic targeting of PAI-1 in STEMI management.
Aim:
To determine the relationship between plasminogen activator inhibitor-1 (PAI-1) activity rise during the first 24 hours of ST-elevation myocardial infarction (STEMI) treatment and death after 5 years.
Methods:
From May 1, 2009 to March 23, 2010, 87 STEMI patients treated with primary percutaneous coronary intervention (PCI) at the Sestre Milosrdnice University Hospital Center were consecutively enrolled in prospective single-center cohort study. PAI-1 activity was determined on admission and 24 hours later. The primary end-point was death after 5 years. The predictive value of PAI-1 activity variables as biomarkers of death was assessed using receiver operating characteristic (ROC) curve, independent predictors of death were assessed using multivariate Cox regression, and covariates independently related to higher PAI-1 activity rise were assessed using linear regression.
Results:
Two patients died during the hospital treatment and 11 during the follow-up. PAI-1 activity rise had the largest area under curve (0.748) for predicting death rate (optimal cut-off point 3.7 U/mL, sensitivity 53.8%, specificity 90.5%). Patients with PAI-1 activity rise higher than 3.7 U/mL had significantly higher mortality (P<0.001). Kaplan-Meier survival curve diverged within the first year after STEMI. Independent predictors of death were PAI-1 rise and final Thrombolysis in Myocardial Infarction flow. PAI-1 activity rise was independently related to heart failure, thrombus aspiration, and body weight.
Conclusion:
PAI-1 activity rise higher than 3.7 U/mL is associated with higher 5-year death rate in STEMI patients treated with primary PCI.
Related Concept Videos
Primary Active Transport
Primary Active Transport
Secondary Active Transport
Co-activators and Co-repressors
tRNA Activation
Activation Energy

